Publications using our products:

Bactosomes, Antibodies, Other

Bactosomes:

Papers: (Posters)

Metabolite Screening of Aromatic Amine Hair Dyes Using in vitro Hepatic Models.
J. A. Skare, N. J. Hewitt, E. Doyle, R. Powrie & C. Elcombe
(The Proctor & Gamble Comapny, Cincinnati, OH, USA
CXR Biosciences Ltd, Dundee, UK)
Xenobiotica  (2009)
Vol 39 (11), p811 - 825

Intramolecular Hydrogen Bonding as a determinant of the Inhibitory Potency of N-unsubstituted Imidazole Derivatives Towards Mammalian Hemoproteins.
L. Perrin, F. André, C. Aninat, R. Ricoux, J-P. Mahy, N. Shangguan, M. M. Joullié & M. Delaforge
(Institut de Biologie et Technologies de Saclay, Gif-sur-Yvette, France
Université de Rennes, Rennes, France
Institut de Chimie Moléculaire et des Matériaux d'Orsay, Université Paris Sud XI, Orsay, France
University of Pennsylvania, Philadelphia, USA)
Metallomics (2009)
Vol 1, p148-156

Novel Metabolites of Amodiaquine Formed by CYP1A1 and CYP1B1: Structure Elucidation Using Electrochemistry, Mass Spectrometry and NMR.
T. Johansson, U. Jarva, G. Grönberg, L. Weidolf & C. Masimirembwa
(AstraZeneca R & D Mölndal, Mölndal, Sweden
University of Gøteborg, Göteborg, Sweden
AIBST, Harare, Zimbabwe)
Drug Metabolism & Disposition (2009)
Vol 37 (3), p571 - 579

In vitro and in silico Identification and Characterisation of Thiabendazole as a Possible Mechanism Based Inhibitor of CYP1A2 and Simulation of Possible Pharmacokinetic Drug-Drug Interactions.
R. S. Thelingwani, S. P. Zvada, H. Dolgos, A-L. B. Ungell & C. M. Masimirembwa
(AIBST, Harare, Zimbabwe
AIBST, University of Capetown, South Africa
AstraZeneca, Mölndal, Sweden)
Drug Metabolism & Disposition  (2009)
Vol 37 (6), p1286 - 1295

In vitro Cytochrome P450 Formation of a Mono-Hydroxylated Metabolite of Zearalenone Exhibiting Estrogenic Activities: Possible Occurence of this Metabolite in vivo.
F. Bravin, R. C. Duca, P. Balaguer & M. Delaforge
(CNRS, Gif sur Yvette, France
IRCM, INSERM, Montpellier, France)
Int. J. Mol. Sci.  (2009)
Vol 10, p1824 - 1837

Cutaneous Metabolic Activation of Carvoxime, a Self-Activating, Skin-Sensitizing Prohapten.
H. Ott, M. A. Bergström, R. Heise, C. Skazik, G. Zwadlo-Klarwasser, H. F. Merk, J. M. Baron & A-T. Karlberg
(RWT Aachen University, Aachen, Germany
Göteborg University, Göteborg, Sweden)
Chem. Res. Toxicol.  (2009)
Vol 22, p399 - 405

Metabolism of Dextrorphan by CYP2D6 in Different Recombinantly Expressed Systems and Its Implications for the in vitro Assessment of Dextromethorphan Metabolism.
L. M. Van, S. Sarda, J. A. Hargreaves & A. Rostami-Hodjegan
(University of Sheffield, Sheffield, UK
AstraZeneca DMPK, MAcclesfield, Cheshire, UK
Simcyp Ltd, Sheffield, UK)
Journal of Pharmaceutical Sciences  (2009)
Vol 98 (2), p763 - 771

Evaluation of Escherichia coli Membrane Preparations of Canine CYP1A1, 2B11, 2C21, 2C41, 2D15, 3A12 and 3A26 with Coexpressed Canine Cytochrome P450 Reductase.
C. W. Locuson, B. T. Ethell, M. W. Voice, D. Lee & K. L. Feenstra
(Pfizer Animal Health, Veterinary Medicine Research & Development, Metabolism & Safety, Kalamazoo, Michigan, USA
Pfizer Global Research & Development Pharmacokinetics, Dynamics & Metabolism, Sandwich, Kent, UK
Cypex Ltd, Dundee, UK
Advantagen Ltd, Dundee, UK)
Drug Metabolism & Disposition  (2009)
Vol 37 (3), p457 - 461

Cytochrome P450-Mediated Activation of the Fragrance Compound Geraniol Forms Potent Allergens.
L. Hagvall, J. M. Baron, A. Björe, L. Weidolf, H. Merk & A-T. Karlberg
(University of Göteborg, Göteborg, Sweden
University Hospital RWTH Aachen, Aachen, Germany
AstraZeneca R & D, Mölndal, Mölndal, Sweden)
Toxicology & Applied Pharmacology  (2008)
Vol 233, p303 - 313

The Molecular Basis of CYP2D6-Mediated N-dealkylation: Balance Between Metabolic Clearance Routes and Enzyme Inhibition.
B. Bonn, C. M. Masimirembwa, Y. Aristei & I. Zamora
(AstraZeneca R & D Mölndal, Mölndal, Sweden
University of Göteborg, Göteborg, Sweden
AIBST, Harare, Zimbabwe
University of Perugia, Perugia, Italy
Lead Molecular Design, Sociedad Limitada, San Cugat del Vallés, Spain
Universitat Pompeu Fabra, Barcelona, Spain)
Drug Metabolism & Disposition (2008)
Vol 36 (11), p2199 - 2210

Potent & Selective Small-molecule Human Urotensin-II Antagonists with Improved Pharmacokinetic Profiles.
J. J. McAtee, J. W. Dodson, S. E. Dowdell, K. Erhard, G. R. Girard, K. B. Goodman, M. A. Hilfer, J. Jin, C. A. Sehon, D. Sha, D. Shi, F. Wang,  G. Z. Wang, N. Wang, Y, Wang, A. Q. Viet, C. C. K. Yuan, D. Zhang, N. V. Aiyar, D. J. Behm, L. H. Carballo, C. A. Evans, H. E. Fries, R. Nagilla, T. J. Roethke, X. Xu,  S. A. Douglas & M. J. Neeb
(GlaxoSmithKline, King of Prussia, PA 19406, USA
GlaxoSmithKline, Research Triangle Park, Morrisville, NC 27703, USA
GlaxoSmithKline, Collegeville, PA19426, USA)
Bioorganic & Medicinal Chemistry Letters (2008)
Vol 18, p3716 - 3719

Development of Potent & Selective Small-molecule Human Urotensin-II Antagonists.
J. J. McAtee, J. W. Dodson, S. E. Dowdell, G. R. Girard, K. B. Goodman, M. A. Hilfer, C. A. Sehon, D. Sha, G. Z. Wang, N. Wang, A. Q. Viet, D. Zhang, N. V. Aiyar, D. J. Behm, L. H. Carballo, C. A. Evans, H. E. Fries, R. Nagilla, T. J. Roethke, X. Xu, C. C. K. Yuan, S. A. Douglas & M. J. Neeb
(GlaxoSmithKline, King of Prussia, PA 19406, USA
GlaxoSmithKline, Research Triangle Park, Morrisville, NC 27703, USA)
Bioorganic & Medicinal Chemistry Letters (2008)
Vol 18, p3500 - 3503

Pharmacology and Metabolism of Renzapride.
N. L. Meyers & R. I. Hickling
(Alizyme Therapeutics Ltd, Cambridge, UK)
Drugs R D (2008)
Vol 9 (1), p37 - 63

Prediction of the Metabolic Interaction of Nateglinide with Other Drugs Based on in vitro Studies.
T. Takanohashi, T. Koizumi, R. Mihara & *K. Okudaira
(Pharmaceutical Company, Ajinomoto Co., Inc., Kawasaki, Japan; *Faculty of Pharmaceutical Sciences, Toho University, Chiba, Japan)
Drug Metabolism & Pharmacokinetics (2007)
Vol 22 (6), p409 - 418

Exploration of Enzyme-Ligand Interactions in CYP2D6 & 3A4 Homolgy Models and Crystal Structures Using a Novel Computational Approach.
B. Kjellander, C. M. Masimirembwa & I. Zamora
(Discovery DMPK, AstraZeneca R&D Mölndal, Sweden
AIBST, Harare, Zimbabwe
Lead Molecular Design, IMIM, Barcelona, Spain)
J. Chem. Inf. Model. (2007)
Vol 47, p1234 - 1247

Silybin is Metabolized by Cytochrome P450 2C8 in vitro.
P. Jančová, E. Anzenbacherová, B. Papoušková, K. Lemr, P. Lužná, A. Veinlichová, P. Anzenbacher & V. Šimánek
(Palacky University at Olomouc, Olomouc, Czech Republic)
Drug Metabolism & Disposition (2007)
Vol 35 (11), p2035 - 2039

Sulfamethoxazole and its Metabolite Nitroso Sulfamethoxasole Stimulate Dendritic Cell Costimulatory Signaling.
J. P. Sanderson, D. J. Naisbitt, J. Farrell, C. A. Ashby, M. J. Tucker, M. J. Rieder, M. Pirmohamed, S. E. Clarke & B. K. Park
(Department of Pharmacology & Therapeutics, University of Liverpool, Liverpool, UK. GlaxoSmithKline, Drug Metabolism & Pharmacokinetics, Ware, Herts, UK.
Dept Medicine, University of Western Ontario, London, Ontario, Canada.)
Journal of Immunology (2007)
Vol 178, p5533 - 5542
(Details use of Bactosomes for time dependent inhibition studies)

The Metabolism of the 5HT3 Antasgonists Ondansetron, Alosetron and GR87442 I: A comparison of in vitro and in vivo Metabolism and in vitro Enzyme Kinetics in Rat, Dog and Human Hepatocytes, Microsomes and Recombinanat Human Enzymes.
G. I. Somers, A. J. Harris, M. K. Bayliss & J. B. Houston
(RI CEDD DMPK, GSK, Stevenage, UK.
Psychiatry CEDD DMPK, GSK, Harlow, UK
University of Manchester, UK)
Xenobiotica (2007)
Vol 37 (8), p832 - 854

Study on the Cytochrome P450 Mediated Oxidative Metabolism of the Terpene Alcohol Linalool: Indication of Biological Epoxidation.
R. J. W. Meesters, M. Duisken & J. Hollender
(Institute of Hygiene & Environmental Medicine, RWTH Aachen University, Aachen, Germany.
LECO Instrumente GmbH, Mönchengladbach, Germany.
Swiss Federal Institute of Aquatic Science and Technology, Eawag, Dübendorf, Switzerland)
Xenobiotica (2007)
Vol 37 (6), p604 - 617

Pharmacokinetic Consequences of Time-Dependent Inhibition using the Isolated Perfused Rat Liver Model.
J.R. Kenny & K. Grime
(Department of Physical & Metabolic Sciences, AstraZeneca R & D, Charnwood, Loughborough, Leicestershire, UK)
Xenobiotica (2006)
Vol 36 (5), p351 - 365

Comparative Analysis of Substrate & Inhibitor Interactions with CYP3A4 and CYP3A5.
M. G. Soars, K. Grime & R. J. Riley
(Department of Physical & Metabolic Science, AstraZeneca R & D, Charnwood, Loughborough, Leicestershire, UK)
Xenobiotica (2006)
Vol 36 (4), p287 - 299

Prediction of CYP2C9-mediated Drug-drug Interactions: A Comparison Using Data from Recombinant Enzymes and Human Hepatocytes. (Downloadable as a pdf)
D. McGinnity, J. Tucker, S. Trigg & R. J. Riley
(AstraZeneca R&D Charnwood, Loughborough, Leicestershire, United Kingdom)
Drug Metabolism & Disposition (2005)
Vol 33, No. 11, p1700 - 1707

Automated Assessment of Time-Dependent Inhibition of Human Cytochrome P450 Enzymes Using Liquid Chromatography-Tandem Mass Spectrometry Analysis. (Downloadable as a pdf)
A. Atkinson, J. R. Kenny & K. Grime
(AstraZeneca R&D Charnwood, Loughborough, Leicestershire, United Kingdom)
Drug Metabolism & Disposition (2005)
Vol 33, No. 11, p1637 - 11647

Pre-clinical Assessment of DRF 4367, a Novel COX-2 Inhibitor: Evaluation of Pharmacokinetics, Absolute Oral Bioavailability and Metabolism in Mice and Comparative Inter-species in vitro Metabolism.(Downloadable as a pdf)
R. Bhamidipati, S. Mujeeb, P. V. Dravid, A. A. Khan, S. K. Singh, Y. K. Rao, R. Mullangi & N. R. Srinivas
(Drug Metabolism & Pharmacokinetics, Discovery Research, Dr Reddy's Laboratories Ltd, Miyapur, Hyderabad, India)
Xenobiotica (2005)
Vol 35 (3), p253 - 271

Metabolism of D3-Carene by Human Cytochrome P450 Enzymes: Identification and Characterisation of Two New Metabolites.(Downloadable as a pdf)
M. Duisken, D. Benz, T. H. Peiffer, B. Blömeke & J. Hollender
(Institute of Hygiene and Environmental Medicine, RWTH Aachen, Pauwelsstraße 30, 52074 Aachen, Germany)
Current Drug Metabolism (2005)
Vol 6, p593 - 601

Metabolism of 1,8-Cineole by Human Cytochrome P450 Enzymes: Identification of a New Hydroxylated Metabolite.(Downloadable as a pdf)
M. Duisken, F. Sandner, B. Blömeke & J. Hollender
(Institute of Hygiene and Environmental Medicine, RWTH Aachen, Pauwelsstraße 30, 52074 Aachen, Germany)
Biochimica et Biophysica Acta (2005)
Vol 1722, p304 - 311

Cytochrome P450-mediated Oxidation of Glucuronide Derivatives: Example of Estradiol-17b-glucuronide Oxidation to 2-hydroxy-estradiol-17b-glucuronide by CYP2C8. (Downloadable as a pdf)
M. Delaforge, A. Pruvost, L. Perrin & F. André
(Service de Pharmacologie et d'Immunologie and Centre National de la Recherche Scientifique, Commisariat à l'Energie Atomique, Saclay, France)
Drug Metabolism & Disposition (2005)
Vol 33, No. 3, p466 - 473

Cytochrome P450 Inhibition Using Recombinant Proteins & Mass Spectroscopy/multiple Reaction Monitoring Technology in a Cassette Incubation. (Downloadable as a pdf)
R. Weaver, K. S. Graham, I. G. Beattie & R. J. Riley
(AstraZeneca R&D Charnwood, Loughborough, Leicestershire, United Kingdom)
Drug Metabolism & Disposition (2003)
Vol 31, No. 37, p955 - 966

A Comparison of Relative Abundance, Activity Factor and Inhibitory Monoclonal Antibody Approaches in the Characterization of Human CYP Enzymology. (Downloadable as a pdf)
M. G. Soars, H. V. Gelboin*, K. W. Krausz* & R. J. Riley
(AstraZeneca R&D Charnwood, Loughborough, Leicestershire, United Kingdom and * Laboratory of Molecular Carcinogenesis, National Cancer Institute, NIH, Bethesda, MD, USA)
British Journal of Clinical Pharmacology (2003)
Vol 55, p175 - 181

A Method for the Simultaneous Evaluation of the Activities of Seven Major Human Drug-metabolising Cytochrome P450s Using an in vitro Cocktail of Probe Substrates and Fast Gradient Liquid Chromatography Tandem Mass Spectroscopy. (Downloadable as a pdf)
E. A. Dierks, K. R. Stams, H-K. Lim, G. Cornelius, H. Zhang & S. Ball
(Wyeth-Ayerst Research, Princeton, New Jersey, USA)
Drug Metabolism & Disposition (2001)
Vol 29, No. 1, p23 - 29

Predicting Drug Pharmacokinetics in Humans from in vitro Metabolism Studies. (Downloadable as a pdf)
D. F. McGinnity & R. J. Riley
(AstraZeneca R&D Charnwood, Loughborough, Leicestershire, United Kingdom)
Biochem. Soc. Trans. (2001)
Vol 29, No. 2, p135 - 139

Automated Definition of the Enzymology of Drug Oxidation by the Major Human Drug Metabolizing Cytochrome P450s. (Downloadable as a pdf)
D. F. McGinnity, A. J. Parker, M. Soars & R. J. Riley
(AstraZeneca R&D Charnwood, Loughborough, Leicestershire, United Kingdom)
Drug Metabolism & Disposition (2000)
Vol 28, No. 11, p1327 - 1334

Fully Automated Analysis of Activities Catalysed by the Major Human Liver Cytochrme P450 (CYP) Enzymes: Assessment of Human CYP Inhibition Potential. (Downloadable as a pdf)
G. C. Moody, S. J. Griffin, A. N. Mather, D. F. McGinnity & R. J. Riley
(AstraZeneca R&D Charnwood, Loughborough, Leicestershire, United Kingdom)
Xenobiotica (1999)
Vol 229, No. 1, p53 - 75

Rapid Characterisation of the Major Drug-metabolising Human Hepatic Cytochrome P-450 Enzymes Expressed in Escherichia Coli. (Downloadable as a pdf)
D. F. McGinnity, S. J. Green, G. C. Moody, M. Voice*, S. Hanlon*, T. Friedberg* & R. J. Riley
(AstraZeneca R&D Charnwood, Loughborough, Leicestershire, United Kingdom and * Biomedical Research Centre, University of Dundee, Ninewells Hospital, Dundee, UK)
Drug Metabolism & Disposition (1999)
Vol 27, No. 9, p1017 - 1023

Posters:

A Comparison of Cytochrome P450 Activities in Bactosomes, Supersomes, and Human Liver Microsomes (Downloadable as a pdf)
K. Settle, A. Madan, B Ogilvie, P. Carrott, A. Hussain & A. Parkinson
XenoTech LLC, 16825 West 116th Street, Lenexa, Kansas 66219, USA
Presented at ISSX 2002, Orlando, USA (Abstract No. 210)

Validation of E. coli-expressed P450 Enzymes for Inhibition Screening. (Downloadable as a pdf)
M.A. Taylor, A. Patel, J.C. Bloomer & S.E. Clarke
Mechanism & Extrapolation Technologies Dept., DMPK, GlaxoSmithKline, The Frythe, Welwyn, Herts, AL6 9AR, UK
Presented at DMDG 2002, Durham, UK

Cocktail Analysis of CYP Inhibition Using MS/MRM Technology and Recombinant Proteins. (Downloadable as a pdf or powerpoint file)
R. Weaver, K. S. Graham, I. G. Beattie & R. J. Riley
Physical & Metabolic Sciences, AstraZeneca R & D Charnwood, Bakewell Road, Loughborough, LE11 5RH, UK
Presented at ISSX 2002, Orlando, USA (Abstract No. 359)

A Comparison of Human Liver Microsomes, Bactosomes and Supersomes for Cytochrome P450 Inhibition Studies (Downloadable as a pdf)
A. Hussain, B Ogilvie & A. Parkinson
XenoTech LLC, 16825 West 116th Street, Lenexa, Kansas 66219, USA
Presented at ISSX 2002, Orlando, USA (Abstract No. 424)

Automated Cytochrome P450 Inhibition Screening. (Downloadable as a pdf)
G. N. Hallam, G. T. Webber & S. G. Wood
BioDynamics Research Ltd, Rushden, Northamptonshire, UK
Presented at 18th European Workshop on Drug Metabolism 2002, Valencia

Recombinant Human CYP1A2 Catalyses the O-demethylation of 7-methoxycoumarin. (Downloadable as a pdf)
S.W. Ayivor, J. Baird & M. Pritchard
Cypex Ltd
Presented at ISSX 2002, Orlando, USA (Abstract No. 91)

Determination of 3,5-diacetyl-1,4-dihydrolutidine Using HPLC with Fluorometric Detection. (Downloadable as a pdf)
J. Baird & M. Pritchard
Cypex Ltd
Presented at ISSX 2002, Orlando, USA (Abstract No. 314)

Enzymatic production of drug metabolites using recombinant human cytochrome P450s. (Downloadable as a pdf)
M. Voice
Cypex Ltd
Presented at RSC DMG 2002, Edinburgh, UK

Determination of 4-methylumbelliferone UGT activity by HPLC with Fluorometric Detection and Application to the Study of Human UGT1A6 Expressed in Escherichia coli. (Downloadable as a pdf)
S. Ayivor & M. Pritchard
Cypex Ltd
Presented at ISSX 2003, Dijon, France (Abstract No. 118)

Determination of 4-methylumbelliferone Sulfotransferase 1A1*1 activity using HPLC with Fluorometric Detection. (Downloadable as a pdf)
J. Baird, M. Pritchard & M. Voice
Cypex Ltd
Presented at ISSX 2003, Providence, Rhode Island USA (Abstract No. 395)

Automated Cytochrome P450 Profiling.(Downloadable as a pdf)
E. N. Gao, R. H. Smith, B. Li, M. C. Secosky, J. W. Gross & A. J. Pope
GlaxoSmithKline, Upper Providence, Pennsylvania, 19426, USA
Presented at SBS 2004

Effects of common organic solvents on the activity of recombinant human cytochrome P450s expressed in E. coli. (Downloadable as a pdf)
J. Baird, C. Begg, M. Pritchard & M. Voice
Cypex Ltd
Presented at ISSX/ JSSX 2005, Maui, Hawaii, USA (Abstract No. 587)

An investigation into the use of 4-methylumbelliferone, p-nitrophenol and 1-naphthol as substrates for recombinant human SULT1B1 expressed in E. coli. (Downloadable as a pdf)
G. Macintyre, M. Pritchard & M. Voice
Cypex Ltd
Presented at ISSX/ JSSX 2005, Maui, Hawaii, USA (Abstract No. 731)

An Inter-laboratory Analysis of Nortryptyline CYP interactions in vitro Confirms Merits of fu_inc Considerations. (Downloadable as a pdf)
P. Roberts, R. J. Riley, R. Swan, D. Slee & M. Whittaker
School of Pharmaceutical Science, University of Central Lancashire, Preston, UK
Presented at ISSX 2006, Manchester, UK (Abstract No. 125)

Cytochrome b₅ Activation of CYP3A4 Activity is Buffer and Reductase Dependent. (Downloadable as a pdf)
G. Macintyre & M. Voice
Cypex Ltd
Presented at ISSX 2007, Sendai, Japan (Abstract No. 143)

Effects of Using Different Assay Buffers on the Activity of Recombinant Human CYP3A4 Co-expressed in E. coli with Human NADPH P450 Reductase. (Downloadable as a pdf)
M. Voice
Cypex Ltd
Presented at ISSX 2007, Sendai, Japan (Abstract No. 142)

CYP2D-synthesized Dopamine in the Brain. The effect of Psychotropics. (Downloadable copy)
E. Bromek, A. Haduch & W. A. Daniel
Institute of Pharmacology, Polish Academy of Sciences, Krakow, Poland
Presented at MDO 2008, Saratoga Springs, USA (Abstract No. 66)

Antibodies:

Keratinocyte Serum-free Medium Maintains Long-term Liver Gene Expression and Function in Cultured Rat Hepatocytes by Preventing the Loss of Liver-enriched Transcription Factors.
W-C. Li, K.L. Ralphs, J.M.W. Slack & D. Tosh
(Centre for Regenerative Medicine, Dept Biology & Biochemistry, University of Bath, Bath, UK)
International Journal of Biochemistry & Cell Biology (2007)
Vol 39, p541 - 554

Characterization of Liver Function in Transdifferentiated Hepatocytes.
Z.D. Burke, C.-N. Shen, K.L. Ralphs & D. Tosh
(Centre for Regenerative Medicine, Dept Biology & Biochemistry, University of Bath, Bath, UK)
Journal of Cellular Physiology (2006)
Vol 206, p147 - 159

Inhibitory Antibodies for Identifying CYP2C8, CYP2C9, CYP2C19 and Other Major Cytochrome P450s. (Downloadable as a pdf)
P-S. Ng, T. Kamataki, T. Hiroi, S. Imaoka & Y. Funae
Bio Department, Nosan Corporation, Landmark Tower 46F, 2-2-1 Minatomirai, Nishiku, Yokohama 220-8146
Presented at MDO 2002, Sapporo, Japan

Specificity and Selectivity of Novel Anti-Human P450 Antibodies. (Downloadable as a pdf)
S. Madden, J. Paton, M. Phillips & B. Cameron
Department of Metabolism Chemistry, Inveresk Research, Tranent, EH33 2NE, UK
Presented at MDO 2002, Sapporo, Japan

Production of Inhibitory Antibodies Against Cytochrome P450s. (Downloadable as a pdf)
P-S. Ng, S. Imaoka, T. Hiroi, M. Osada, T. Niwa, T. Kamataki, & Y. Funae (2003)
Drug Metab. Pharmacokin. 18 (3): pp 163 - 172

Other:

Analysis of the Expression of CYP3A4 and CYP3A5 mRNAs in Human Liver by Branched DNA (bDNA) Assay (Downloadable as a pdf)
M. Czerwinski, D. Mudra, A. Madan, M. Voice* & A. Parkinson
XenoTech LLC, 16825 West 116th Street, Lenexa, Kansas 66219, USA
*Cypex Ltd

Use of Specific Radiolabelled Metabolite Standards in the Optimisation of Drug Metabolising Assays. (Downloadable as a pdf)
G. T. Webber, R. Cole, V. Pope, S. Hollis, S. D'Hainaut, G. Johnston & S. G. Wood
BioDynamics Research Ltd, Rushden, Northamptonshire, NN10 6ER UK
Presented at ISSX 2003, Dijon, France

Incorporation of Laurate and Hydroxylaurate into Phosphatidyl Cholines and Acylglycerols in Castor Microsomes.
Jiann-Tsyh Lin, Seiji Wani, Xiaohua He, Tasha Nguyen & Thomas A. McKeon.
Western Regional Research Center, ARS, USDA, Albany, California 94710, USA
J. Am. Oil Chem. Soc. (2005) 82 (7), p495 - 499